SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to alleged violations of federal securities laws, encouraging affected investors to seek legal counsel before the August 11, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [3][5]. Group 1: Allegations Against PepGen - The complaint alleges that PepGen and its executives made false or misleading statements regarding the effectiveness and safety of PGN-EDO51, and failed to disclose deficiencies in the CONNECT2 study, leading to overstated clinical and commercial prospects [5]. - The FDA issued a clinical hold notice for the CONNECT2 study, indicating concerns about patient risks and deficiencies in the study [8]. Group 2: Stock Price Reactions - Following the announcement of disappointing clinical data from the CONNECT1 study, PepGen's stock price fell by $5.55, or 32.69%, closing at $11.43 on July 31, 2024 [7]. - After the FDA's clinical hold notice on December 16, 2024, PepGen's stock dropped by $0.17, or 3.63%, to close at $4.51 [9]. - On January 30, 2025, PepGen's stock fell by $0.40, or 21.74%, to close at $1.44 after updates on safety concerns in the CONNECT1 study [10]. - The stock price further declined by $0.53, or 18.86%, to close at $2.28 on March 4, 2025, following the announcement to pause the CONNECT2 study [11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12]. Group 3: Legal and Investor Actions - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi for legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding PepGen's conduct [14].